Trials / Completed
CompletedNCT02053220
Mechanism of Action Trial of ColoAd1
A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Akamis Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following ColoAd1 administration by intravenous infusion.
Conditions
- Resectable Colon Cancer
- Resectable Non-small Cell Lung Cancer
- Resectable Bladder Cancer
- Resectable Renal Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Colo-Ad1 | Oncolytic virus |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2015-04-01
- Completion
- 2016-04-01
- First posted
- 2014-02-03
- Last updated
- 2020-03-12
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02053220. Inclusion in this directory is not an endorsement.